TrialStat EDC

Fast, Compliant, Fully Unified – EDC + IWRS + ePRO + Coding

TrialStat Portal

Real-Time Data & Analytics | Make Study Decision Sooner

Don't Settle For Standard EDC Technology & Services

With TrialStat EDC you'll have your studies up and running quicker, capture your study data more efficiently with fewer errors and reduce your overall study costs.

We're Supporting COVID-19 Research

In times of crisis we all need to step up and help. Effective immediately, we are offering TrialStat’s eClinical Platform and Data Analytics Portal at discounted rates to researchers working on solutions related to COVID-19. With a focus on ease of use, speed of implementation, and real-time data analytics, TrialStat’s data capture suite enables fast study start up and ensures all stakeholders have relevant, customized, timely insight into all aspects of study data and areas of risk or potential delays. We welcome the opportunity to collaborate with our industry colleagues on the path to treatments or cures – please contact [email protected] to learn more about this program.

Have questions about enrolling in a clinical trial, or about the COVID-19 Vaccines?

If you're a member of the general public and have questions about the approved vaccines, or are interested in enrolling in a clinical trial please have a look at the following resources:

From the entire TrialStat team, we wish you and yours good health as our industry and our communities work together to navigate this outbreak over the coming weeks and months. Thank you for #StayingHome and #FlatteningTheCurve!


Our Latest COVID-19 Research News

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

TFF Pharmaceuticals and Augmenta Bioworks Publish Positive In Vivo Data Showing Dry Powder Formulation of COVID-19 Antibody, AUG-3387, Neutralizes SARS-CoV-2 Infection and Reduces Viral Load

Results published in bioRxiv Show That Delivery of Dry Powder AUG-3387 Following Viral Inoculation Led to Dose-Dependent Reduction in Lung ...
Read More

NeuroBo Pharmaceuticals Announces Positive Recommendation from Independent Data Safety Monitoring Committee of Phase 2/3 Clinical Trial of ANA001 in Hospitalized Patients with Moderate to Severe COVID-19

Committee Advises Continuation of Trial Without Modification Excerpt from the Press Release: BOSTON, Oct. 13, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), ...
Read More

Inhalable anti-COVID-19 antibody from TFF and Augmenta tamps down viral load in hamsters

Excerpt from the Press Release: When startup TFF Pharmaceuticals raised $14 million in a series A in 2018, ...
Read More

New Duke University-led Study Shows That Vaxart’s Oral COVID-19 Vaccine Candidate Reduces Airborne Transmission of SARS-CoV-2 Infection in Animal Model

Data published in bioRxiv confirmed previous findings suggesting mucosal vaccines could reduce transmission of airborne viruses such as ...
Read More

India’s Bharat Biotech submits data on COVID-19 drug trial in children

Excerpt from the Press Release: BENGALURU, Oct 6 (Reuters) - Bharat Biotech said on Wednesday it had submitted ...
Read More

Protecting cancer patients from COVID-19: world-first clinical trial tests a novel immune-boosting strategy

Excerpt from the Press Release In the race to find new ways to prevent and treat COVID-19, OICR-supported ...
Read More

Trevena Announces Results of TRV027 Proof-of-Concept Study in COVID-19 Patients

92% probability that TRV027 has a potential beneficial impact on primary endpoint of D-dimer levels, a biomarker associated ...
Read More

Data Presented at IDWeek™ 2021 Demonstrate that ALVR109, AlloVir’s Investigational SARS-CoV-2-Specific T Cell Therapy, Is Reactive Against a Broad Range of Variants, Including Delta

Early clinical data show expansion and persistence of cells and support the efficacy and safety profile of ALVR109 ...
Read More

VBI Vaccines Announces New Preclinical Data and Initiation of VBI-2905 Clinical Study Targeting Broadened Immunity Against COVID-19 and Variants of Concern

New preclinical data demonstrate VBI-2905 induced robust neutralizing and antibody binding activity, as a 2-dose course and as ...
Read More